Related Experiment Video
Updated: Jun 2, 2026
07:48
Preparing a 68Ga-labeled Arginine Glycine Aspartate (RGD)-peptide for Angiogenesis
Published on: January 7, 2019
Macrocyclic chelator assembled RGD multimers for tumor targeting
Xiaofen Zhang1, Hongguang Liu, Zheng Miao
1Molecular Imaging Program at Stanford, Department of Radiology, Stanford University Medical Center, California 94305, USA.
Bioorganic & Medicinal Chemistry Letters
|April 29, 2011
Summary
Macrocyclic chelators like DOTA can be used to create multivalent peptide bioconjugates. These novel DOTA-peptide constructs show significant potential for effective tumor targeting in medical applications.
Area of Science:
- Bioconjugation Chemistry
- Medicinal Chemistry
- Nanomedicine
Background:
- Macrocyclic chelators are essential for metal ion complexation.
- DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) is a widely utilized chelator.
- Developing targeted drug delivery systems is crucial for cancer therapy.
Purpose of the Study:
- To explore DOTA as a molecular platform for assembling multiple bioactive peptides.
- To synthesize and characterize novel DOTA-peptide bioconjugates.
- To evaluate the tumor targeting efficacy of these multivalent bioconjugates.
Main Methods:
- Synthesis of DOTA-peptide conjugates.
- Characterization of the bioconjugates.
- In vitro and in vivo studies to assess tumor targeting ability.
Main Results:
- Successful assembly of multiple bioactive peptides onto the DOTA platform.
- Demonstrated stability and integrity of the DOTA-peptide bioconjugates.
- Promising results in targeting tumor sites, indicating high specificity and efficacy.
Conclusions:
- DOTA serves as an effective molecular scaffold for creating multivalent peptide bioconjugates.
- These DOTA-peptide bioconjugates exhibit significant potential for targeted cancer therapy.
- Further research into DOTA-based targeted delivery systems is warranted.
